New combo therapy targets tough breast cancer
NCT ID NCT02802423
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced triple negative breast cancer, a type that is harder to treat. It tests a new oral liquid drug called BLEX 404 given with the chemotherapy drug Docetaxel. The goal is to find a safe dose and see if the combination helps shrink tumors. About 44 participants will take part in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can a new nucleotide analogue boost cancer treatment?